10x Genomics (TXG) Misses Q4 EPS by 7c

10x Genomics (NASDAQ: TXG) reported Q4 EPS of ($0.16), $0.07 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $143.5 million versus the consensus estimate of $148.53 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $600-630 million, versus the consensus of $679 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Constellation Brands (STZ) Tops Q1 EPS by 18c
• Evercore ISI Upgrades XPO (XPO) to Outperform
• JPMorgan Upgrades Perpetual Ltd (PPT:AU) (PRPLF) to Overweight